Loading...

We've got a brand new version of Simply Wall St! Try it out

Patrys

ASX:PAB
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PAB
ASX
A$21M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. The last earnings update was 88 days ago. More info.


Add to Portfolio Compare Print
PAB Share Price and Events
7 Day Returns
0%
ASX:PAB
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-28.6%
ASX:PAB
50.9%
AU Biotechs
16.3%
AU Market
PAB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Patrys (PAB) 0% -13% -9.1% -28.6% 233.3% 17.6%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • PAB underperformed the Biotechs industry which returned 50.9% over the past year.
  • PAB underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
PAB
Industry
5yr Volatility vs Market

PAB Value

 Is Patrys undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Patrys. This is due to cash flow or dividend data being unavailable. The share price is A$0.02.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Patrys's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Patrys's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:PAB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$0.00
ASX:PAB Share Price ** ASX (2019-11-17) in AUD A$0.02
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Patrys.

ASX:PAB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:PAB Share Price ÷ EPS (both in AUD)

= 0.02 ÷ 0.00

-52.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Patrys is loss making, we can't compare its value to the Global Biotechs industry average.
  • Patrys is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Patrys's expected growth come at a high price?
Raw Data
ASX:PAB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -52.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Patrys, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Patrys's assets?
Raw Data
ASX:PAB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.01
ASX:PAB Share Price * ASX (2019-11-17) in AUD A$0.02
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:PAB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:PAB Share Price ÷ Book Value per Share (both in AUD)

= 0.02 ÷ 0.01

2.94x

* Primary Listing of Patrys.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Patrys is good value based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Patrys's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Patrys has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PAB Future Performance

 How is Patrys expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Patrys has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Patrys expected to grow at an attractive rate?
  • Unable to compare Patrys's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Patrys's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Patrys's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:PAB Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:PAB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:PAB Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 1 0 0
2019-03-31 1 0 -1
2018-12-31 1 0 -1
2018-09-30 1 -1 -2
2018-06-30 1 -2 -2
2018-03-31 0 -2 -2
2017-12-31 0 -2 -2
2017-09-30 0 -2 -1
2017-06-30 1 -1 -1
2017-03-31 1 -1 -1
2016-12-31 1 -1 -1
2016-09-30 1 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Patrys is high growth as no earnings estimate data is available.
  • Unable to determine if Patrys is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:PAB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Patrys Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PAB Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 0.00
2019-03-31 0.00
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 0.00
2016-09-30 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Patrys will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Patrys's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Patrys's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Patrys's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Patrys's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Patrys has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PAB Past Performance

  How has Patrys performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Patrys's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Patrys does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Patrys's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Patrys's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Patrys's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Patrys Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PAB Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.84 -0.41 2.57 1.69
2019-03-31 0.68 -0.51 2.59 1.60
2018-12-31 0.51 -0.61 2.62 1.51
2018-09-30 0.52 -1.55 2.17 1.41
2018-06-30 0.52 -2.50 1.71 1.31
2018-03-31 0.48 -2.02 1.47 1.21
2017-12-31 0.44 -1.55 1.24 1.11
2017-09-30 0.48 -1.30 1.19 1.19
2017-06-30 0.53 -1.06 1.15 1.27
2017-03-31 0.57 -1.03 0.96 1.22
2016-12-31 0.60 -1.01 0.77 1.18
2016-09-30 0.73 -1.04 0.83 1.11
2016-06-30 0.87 -1.08 0.88 1.04
2016-03-31 1.23 -3.72 0.95 1.54
2015-12-31 1.59 -6.36 1.01 2.05
2015-09-30 1.91 -7.41 1.02 3.36
2015-06-30 2.22 -8.47 1.03 4.67
2015-03-31 1.74 -7.59 1.26 5.59
2014-12-31 1.26 -6.72 1.48 6.50
2014-09-30 1.01 -7.00 1.61 6.40
2014-06-30 0.76 -7.29 1.74 6.30
2014-03-31 0.78 -6.41 1.65 5.63
2013-12-31 0.81 -5.52 1.56 4.96
2013-09-30 0.89 -4.53 1.48 4.13
2013-06-30 0.98 -3.53 1.40 3.30
2013-03-31 1.38 -2.95 1.37 3.05
2012-12-31 1.78 -2.36 1.34 2.80

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Patrys has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Patrys has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Patrys improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Patrys's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Patrys has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PAB Health

 How is Patrys's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Patrys's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Patrys is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Patrys's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Patrys's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Patrys has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Patrys Company Filings, last reported 4 months ago.

ASX:PAB Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 7.30 0.00 6.47
2019-03-31 7.30 0.00 6.47
2018-12-31 8.39 0.00 8.15
2018-09-30 8.39 0.00 8.15
2018-06-30 7.29 0.00 6.61
2018-03-31 7.29 0.00 6.61
2017-12-31 1.67 0.00 0.91
2017-09-30 1.67 0.00 0.91
2017-06-30 2.66 0.00 1.91
2017-03-31 2.66 0.00 1.91
2016-12-31 3.18 0.00 2.71
2016-09-30 3.18 0.00 2.71
2016-06-30 3.64 0.00 3.22
2016-03-31 3.64 0.00 3.22
2015-12-31 3.41 0.00 4.01
2015-09-30 3.41 0.00 4.01
2015-06-30 3.97 0.00 4.65
2015-03-31 3.97 0.00 4.65
2014-12-31 9.75 0.00 5.45
2014-09-30 9.75 0.00 5.45
2014-06-30 12.43 0.00 8.64
2014-03-31 12.43 0.00 8.64
2013-12-31 14.21 0.00 10.32
2013-09-30 14.21 0.00 10.32
2013-06-30 10.77 0.00 5.23
2013-03-31 10.77 0.00 5.23
2012-12-31 12.98 0.00 6.09
  • Patrys has no debt.
  • Patrys has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Patrys has sufficient cash runway for more than 3 years based on current free cash flow.
  • Patrys has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -39.4% each year.
X
Financial health checks
We assess Patrys's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Patrys has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PAB Dividends

 What is Patrys's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Patrys dividends.
If you bought A$2,000 of Patrys shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Patrys's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Patrys's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:PAB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Patrys has not reported any payouts.
  • Unable to verify if Patrys's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Patrys's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Patrys has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Patrys's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Patrys afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Patrys has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PAB Management

 What is the CEO of Patrys's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
James Campbell
COMPENSATION A$503,674
TENURE AS CEO 4.6 years
CEO Bio

Dr. James A. Campbell, BSc(Hons), PhD, MBA, GAICD serves as Chief Executive Officer and Managing Director for Patrys Limited since April 13, 2015. Dr. Campbell serves as Principal of Gemini Biotechnology. Dr. Campbell is a Co-founder of Vitality Devices Pty Limited and serves as its Chief Executive Officer and Managing Director. He served as the Chief Financial Officer and Corporate Advisor of Evolve Biosystems, Inc. He served as an Executive at ChemGenex for 9 years. He served as Executive of Booz Allen Hamilton Holding Corporation. He served as the Chief Financial Officer and Chief Operating Officer of Chemgenex Pharmaceuticals Ltd. since April 2009. He served as Vice President of Operations at Chemgenex Pharmaceuticals Ltd. He also served as Company Secretary of Chemgenex Pharmaceuticals Ltd. from April 2009 to July 1, 2011. Dr. Campbell has more than 20 years’ experience in scientific research, research management, management consulting and venture capital in Australia and internationally. Dr. Campbell later joined the University of Melbourne, where he was instrumental in the spin-out of four biotechnology companies. He served as Director of Business Development of Chemgenex. Dr. Campbell held research positions at the CNRS and the CSIRO. He worked for the international management consultancy Booz Allen Hamilton. He has been a Non-Executive Director of Patrys Limited since November 12, 2014 and Prescient Therapeutics Limited (alternate name, Virax Holdings Ltd.) since November 28, 2014. He served as a Non-Executive Director of Medibio Limited (formerly BioProspect Ltd.) from September 8, 2014 to September 30, 2016. He serves as Director at Vitality Devices Pty Limited. He serves as Executive Director of CBio Limited. He serves as Director of Hatchtech Pty Ltd and Pargenex Pty Ltd. He has been a Non-Executive Director of Invion Limited (formerly known as CBio Limited) since February 26, 2012. He served as an Executive Director of Invion Limited until October 14, 2013. Dr. Campbell serves on the Victorian State Government Advisory Committee on Biotechnology Investment Attraction/Competitive Business Environment. Dr. Campbell is a past member of the investment committees of the pre-seed venture capital funds UniSeed and the Symbiosis Group. He completed his MBA from Melbourne Business School in the University of Melbourne, PhD from Deakin University and BS from The University of Melbourne.

CEO Compensation
  • James's compensation has increased whilst company is loss making.
  • James's remuneration is higher than average for companies of similar size in Australia.
Management Team

James Campbell

TITLE
MD, CEO & Director
COMPENSATION
A$504K
TENURE
4.6 yrs

Melanie Jaye Leydin

TITLE
Company Secretary
COMPENSATION
A$104K
AGE
46
TENURE
4.1 yrs

Deanne Greenwood

TITLE
Vice President of Business Development & Intellectual Property
COMPENSATION
A$146K
Board of Directors

John Read

TITLE
Non-Executive Chairman
COMPENSATION
A$168K

James Campbell

TITLE
MD, CEO & Director
COMPENSATION
A$504K
TENURE
5 yrs

Mike Stork

TITLE
Deputy Chairman
COMPENSATION
A$58K

John Zalcber

TITLE
Clinical Advisor
AGE
67

Chris Sweeney

TITLE
Clinical Advisor

Pete Gagnon

TITLE
Manufacturing Advisor

Kent Iverson

TITLE
Manufacturing Advisor

Bertram Illert

TITLE
Clinical Advisor

Stephanie Brändlein

TITLE
Scientific Advisor

Suzy Jones

TITLE
Non-Executive Director
COMPENSATION
A$142K
AGE
53
TENURE
7.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
10. Jul 19 Sell Macquarie Investment Management Limited Company 04. Sep 18 05. Jul 19 -83,215,586 A$0.05 A$-4,160,771
10. Jul 19 Buy Macquarie Investment Management Limited Company 30. Aug 18 05. Jul 19 19,542,985 A$0.05 A$977,147
X
Management checks
We assess Patrys's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Patrys has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PAB News

Simply Wall St News

How Much Of Patrys Limited (ASX:PAB) Do Insiders Own?

Taking a look at our data on the ownership groups (below), it's seems that institutions own shares in the company. … View our latest analysis for Patrys ASX:PAB Ownership Summary, August 8th 2019 What Does The Institutional Ownership Tell Us About Patrys? … Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Simply Wall St -

If You Had Bought Patrys (ASX:PAB) Stock Three Years Ago, You Could Pocket A 300% Gain Today

Investors should note that there's a difference between Patrys's total shareholder return (TSR) and its share price change, which we've covered above. … Patrys hasn't been paying dividends, but its TSR of 315% exceeds its share price return of 300%, implying it has either spun-off a business, or raised capital at a discount; thereby providing additional value to shareholders. … A Different Perspective Investors in Patrys had a tough year, with a total loss of 56%, against a market gain of about 12%.

Simply Wall St -

Should You Worry About Patrys Limited's (ASX:PAB) CEO Pay?

In 2015 James Campbell was appointed CEO of Patrys Limited (ASX:PAB). … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does James Campbell's Compensation Compare With Similar Sized Companies?

Simply Wall St -

How Much Are Patrys Limited (ASX:PAB) Insiders Spending On Buying Shares?

In the last twelve months, the biggest single purchase by an insider was when Dax Calder bought AU$100k worth of shares at a price of AU$0.034 per share. … That means that an insider was happy to buy shares at above the current price of AU$0.024. … It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels

Simply Wall St -

Investors Who Bought Patrys Shares Three Years Ago Are Now Up 200%

It hasn't been the best quarter for Patrys Limited (ASX:PAB) shareholders, since the share price has fallen 19% in that time. … There is almost always a chance they will need to raise more capital, and their progress - and share price - will dictate how dilutive that is to current holders. … And given that the share price has shot up 44% per year, over 3 years, its fair to say investors are liking management's vision for the future.

Simply Wall St -

How Much Of Patrys Limited (ASX:PAB) Do Insiders Own?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Patrys is a smaller company with a market capitalization of AU$27m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company

Simply Wall St -

Is Patrys Limited (ASX:PAB) Overpaying Its CEO?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does James Campbell's Compensation Compare With Similar Sized Companies. … Our data indicates that Patrys Limited is worth AU$30m, and total annual CEO compensation is AU$399k.

Simply Wall St -

What Investors Should Know About Patrys Limited's (ASX:PAB) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is PAB right in choosing financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

What Kind Of Investor Owns Most Of Patrys Limited (ASX:PAB)?

The big shareholder groups in Patrys Limited (ASX:PAB) have power over the company. … With a market capitalization of AU$30m, Patrys is a small cap stock, so it might not be well known by many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Should You Worry About Patrys Limited's (ASX:PAB) CEO Pay?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does James Campbell's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below AU$282m.

Simply Wall St -

PAB Company Info

Description

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates live cell nuclei and inhibits mechanisms of DNA repair in target cancer cells. The company also focuses on developing PAT-DX1 as a treatment for metastatic triple negative breast cancer and glioblastoma. In addition, it engages in developing PAT-SC1’s target/antigen CD55PAT-SC1, an isoform of the membrane-bound CD55 for the treatment of gastric cancer. Patrys Limited was founded in 2006 and is based in South Melbourne, Australia.

Details
Name: Patrys Limited
PAB
Exchange: ASX
Founded: 2006
A$20,897,148
1,071,648,659
Website: http://www.patrys.com
Address: Patrys Limited
100 Albert Road,
Level 4,
South Melbourne,
Victoria, 3205,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX PAB Ordinary Shares Australian Securities Exchange AU AUD 13. Jul 2007
CHIA PAB Ordinary Shares Chi-X Australia AU AUD 13. Jul 2007
Number of employees
Current staff
Staff numbers
0
Patrys employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:35
End of day share price update: 2019/11/17 00:00
Last earnings filing: 2019/08/22
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.